Jermasek Douglas 4
4 · Unicycive Therapeutics, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Unicycive (UNCY) EVP Douglas Jermasek Receives RSU Award
What Happened
- Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics (UNCY), received a grant of 169,500 restricted stock units (RSUs) reported as an award on May 14, 2026. The Form 4 lists the acquisition price as $0.00 because this is a compensation award (derivative security), not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-05-14 (reported on Form 4 filed 2026-05-20).
- Security and amount: 169,500 restricted stock units (derivative award) at $0.00 per share.
- Vesting: RSUs vest 1/3 on each anniversary of the grant for 3 years, subject to continued service (per footnote).
- Shares owned after transaction: Not stated on the filing.
- Timeliness: Form 4 filed 6 days after the grant (appears to be a late filing).
Context
- RSUs convert to common stock only as they vest; there was no immediate cash payment or open‑market trade reported. Such awards are common executive compensation and do not, by themselves, indicate a buy or sell decision by the insider. The late filing is an administrative compliance issue worth noting for monitoring insider reporting practices.
Insider Transaction Report
Form 4
Jermasek Douglas
EVP, Corporate Strategy
Transactions
- Award
Restricted Stock Units
[F1]2026-05-14+169,500→ 169,500 totalExercise: $0.00→ Common Stock (169,500 underlying)
Footnotes (1)
- [F1]Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.
Signature
/s/ Doug Jermasek|2026-05-20